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Optimization of Stent Deployment by intravascular 
Ultrasound
Hyuck-Jun Yoon and Seung-Ho Hur
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Intravascular ultrasound (IVUS) is a useful diagnostic method that provides valuable information in addition to angiog-
raphy regarding the coronary vessel lumen, dimensions, plaque burden, and characteristics. The major use of IVUS in 
coronary intervention is to guide interventional strategies and assess optimal stent deployment. Since the introduction 
of the drug-eluting stent (DES), concerns about restenosis have decreased. However, high-risk lesion subsets are being 
routinely treated with DESs, and the incidence of suboptimal results after stent deployment, such as stent underexpan-
sion, incomplete stent apposition, edge dissection, geographic miss, and the risk of stent thrombosis, have correspond-
ingly increased. Thus, optimization of stent deployment under IVUS guidance may be clinically important. In this review, 
we focus on the potential role of IVUS in stent optimization during percutaneous coronary intervention and its clinical 
benefits.
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IntRoDuCtIon
The coronary angiogram (CAG) remains the gold-stan-
dard method for assessing coronary artery disease (CAD). 
However, the CAG has inherent pitfalls, such as only show-
ing the vessel lumen as an X-ray shadow image, created by 
the injection of contrast medium, and of often visualizing 
a “side-view.” Thus, the apparent degree of coronary ste-
nosis can be affected by the projection angle due to lesion 
eccentricity. Additionally, diffuse coronary disease, lesion 
foreshortening, angulations, calcification, and vessel over-
lap can be challenges in the angiographic assessment of le-
sion severity. In some cases, an angiographically normal-
looking coronary artery actually shows various degrees of 
atherosclerotic plaque by intravascular ultrasound (IVUS) 
[1,2].
IVUS is an invasive imaging technique used to visualize 
coronary cross-sectional anatomy and is superior to CAG 
in assessing vessel size, calcium content, and lesion sever-
ity [3]. It also provides complementary procedural infor-
mation in lesions requiring percutaneous coronary inter-
vention (PCI) when determining adequate stent sizing, 
and confirming optimal stent deployment and apposition 
without edge tearing in real time. Thus, a growing number 
of interventional cardiologists attain optimal procedural 
results with reduced complications when using IVUS in 
PCI.
Although the routine use of IVUS in daily PCI remains 
controversial, stent optimization by IVUS during stenting 
procedures, especially in the era of drug-eluting stents Yoon HJ and Hur SH. IVUS-guided stent optimization    31
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(DESs), may have an important role in improving long-
term clinical outcomes such as stent restenosis and stent 
thrombosis [4]. In this review, we focus on the potential 
roles of IVUS in stent optimization during PCI and its 
clinical benefits.
ReAlIty of StentIng pRoCeDuReS In 
DAIly pRACtICe
PCI has been the fastest growing method for the treat-
ment of ischemic CAD over the past three decades. 
Coronary stents have emerged as the predominant form 
of PCI and are currently used in more than 90% of PCI 
procedures. Procedural success of PCI is usually deter-
mined by visual estimation by the operator, and usually, 
angiographic success after PCI is defined as the attain-
ment of residual diameter stenosis of less than 30%, which 
is generally associated with at least a 20% improvement in 
diameter stenosis and relief of ischemia [5]. However, such 
subjective estimation of the severity of coronary artery ste-
nosis is thought to be of limited reliability. Previous IVUS 
studies have demonstrated that visual estimation or quan-
titative angiographic analyses of vessel dimension for stent 
deployment appear inaccurate [6-9]. The post-dilatation 
clinical comparative (POSTIT) trial was designed to assess 
the achievement of optimal stent deployment by IVUS, 
according to normal-to-high pressure balloon dilation 
after bare metal stent implantation. Among 256 patients, 
only 14% of cases achieved optimal stent deployment with 
under 12-atmosphere pressure dilation and only 36% even 
with higher deployment pressures (> 14 atmospheres) [9]. 
Another IVUS study with an early-generation DES in 200 
patients assessed stent expansion depending on the manu-
facturer’s compliance chart as a guideline. In that study, 
the DES obtained only 75% of predicted minimal stent di-
ameter and 66% of the predicted minimal stent area (MSA) 
[10] (Fig. 1). Based on these observations, angiographic 
success cannot always be linked with optimal stent ex-
pansion, despite higher pressure balloon inflation during 
the stenting procedure. In turn, stent optimization using 
a high-pressure balloon without IVUS guidance also has 
been associated with an increased risk of arterial perfora-
tion, probably secondary to vessel-balloon mismatch [11]. 
Thus, the operator should consider using IVUS guidance 
for high-pressure balloon inflation during stent deploy-
ment.
Apposition of stent struts to the vessel wall is also an 
important facet of stent optimization. Adequate stent 
expansion and adequate stent strut apposition have been 
reported to be important factors in reducing repeated re-
vascularization due to stent restenosis or stent thrombosis 
[12,13]. In the DES era, incomplete stent apposition has 
been regarded as an important local factor in DES failure, 
probably due to reduced drug delivery to the vessel wall 
[14-17]. In a recent report, incomplete stent apposition was 
significantly associated with vessel/stent mismatch rather 
than stent underexpansion immediately after stent im-
plantation [18]. Thus, adequate stent sizing by IVUS may 
be clinically important in preventing incomplete stent ap-
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Figure 1. Intravascular ultrasound (IVUS)-measured minimum stent diameter (MSD, A) and minimum stent area (MSA, B) vs. pre-
dicted measurements from each manufacturer’s compliance charts. SES, sirolimus-eluting stent; PES, paclitaxel-eluting stent. Reprint 
with permission from Elsevier Health Science Journals [10].
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position and in optimizing initial stent deployment.
IMpoRtAnCe of Stent optIMIzAtIon
IVUS has been used to detect suboptimal results after 
apparently angiographically successful stent deployment 
in both the DES and bare metal stent (BMS) eras (Fig. 2). 
IVUS predictors that are associated with increased ad-
verse outcomes include smaller MSA, stent underexpan-
sion, stent edge dissection, incomplete stent apposition, 
and incomplete lesion coverage [19-26]. In the BMS era, a 
major problem after stent implantation was stent resteno-
sis, and the main mechanism of this phenomenon was a 
smaller MSA or stent underexpansion [21,26-30]. Several 
studies in the BMS era showed a beneficial effect of IVUS 
guidance on post-procedural angiographic results and 
stent restenosis during long-term follow-up, resulting from 
a larger MSA with a higher post-dilation balloon pressure 
[7,19,27,31]. Stent underexpansion, identified by IVUS, can 
be treated with appropriate post-balloon dilation. IVUS 
allows more aggressive intervention using a larger diam-
eter balloon with confidence in terms of safety; thus, BMS 
implantation under IVUS guidance can provide a bigger 
MSA and more favorable clinical outcomes compared 
with angiography-guided PCI. DESs have led to a marked 
reduction in the rate of stent restenosis and the need for 
repeated revascularization compared with BMSs [32,33]. 
Because of their efficacy, high-risk lesions and clinical 
conditions, including bifurcation lesions, long lesions, cal-
cified lesions, left main disease, diabetes, and multivessel 
disease, are now being treated routinely with DESs [34,35]. 
Thus, the risk of stent underexpansion, incomplete stent 
apposition, and incomplete lesion coverage increases and 
these suboptimal stent deployment conditions have been 
reported to be potent IVUS predictors of stent resteno-
sis and stent thrombosis [13,17,24], suggesting that stent 
implantation under IVUS guidance still has a pivotal role 
even in the DES era. An important aspect of IVUS is de-
termining appropriate reference segments that provide 
the landing zone for stent deployment. IVUS examination 
typically reveals a considerable amount of plaque, even in 
segments of the vessel that appear “normal” on the angio-
gram, known as “reference vessel” disease. Quantitative 
IVUS studies have demonstrated that the segment chosen 
as the “normal” reference site for the calculation of angio-
graphic percent stenosis has an average of 30-50% of its 
cross-sectional area occupied by plaque [36]. By IVUS, the 
definition of reference segment is a cross-sectional image 
adjacent to the lesion that has < 40% plaque burden [37]. 
A previous study reported the association between clinical 
outcomes and longitudinal positioning of the stent in 162 
consecutive patients with 180 lesions treated with siroli-
mus-eluting stent (SES) implantation [38]. In that study, 
stepwise IVUS criteria primarily targeting plaque burden 
< 50% were shown to be feasible and improved the rates of 
stent restenosis and target lesion revascularization (TLR) 
at 8 months follow-up.
How to optIMIze Stent DeployMent
IVUS is used frequently in PCI, but the use of IVUS 
cannot be directly related to stent optimization. Defini-
tive guidelines for IVUS-guided stent optimization are 
not available and it is still performed at the operator’s dis-
cretion. So, how do we perform stent optimization using 
IVUS, and what IVUS criteria are acceptable for current 
practice?
Although many IVUS criteria for stent optimization 
have been suggested, the basic concepts underlying them 
can be summarized briefly as minimizing the occurrence 
of IVUS-related predictors of adverse events after PCI, 
including stent underexpansion, incomplete stent apposi-
tion, edge dissection, and lesion undercoverage.
Stent underexpansion is defined as an area of inad-
equate stent expansion compared with the adjacent refer-
Incomplete  
stent apposition 
Stent 
underexpansion 
Edge 
dissection 
Figure 2. Stent-related complications after stent deployment.Yoon HJ and Hur SH. IVUS-guided stent optimization    33
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ence segments. However, a consensus definition of “ad-
equate” expansion is still lacking.
In the BMS era, several randomized trials used various 
IVUS criteria for stent deployment optimization, yield-
ing mixed results. The first large multicenter study, called 
MUSIC (multicenter ultrasound stenting in coronaries 
study), sought to define specific criteria for optimal stent 
deployment and demonstrate the feasibility and safety of 
IVUS-guided stent optimization [39]. In the MUSIC cri-
teria, “adequate” expansion was defined as > 90% of the 
average reference cross-sectional area (CSA), or > 100% 
of a smaller reference CSA with complete apposition and 
symmetric expansion. Another large multicenter trial was 
AVID (angiographic versus IVUS direct stent placement); 
its defined IVUS optimization required complete stent 
apposition with stent CSA > 90% of the distal reference 
lumen area [40]. The results of the AVID trial showed a 
significant benefit of IVUS guidance in vessels 2.5-3.5 mm 
in size and in saphenous vein graft PCI. The TULIP 
(thrombotic activity evaluation and effects of ultrasound 
guidance in long intracoronary stent placement) Study 
also showed significant angiographic and clinical benefits 
of IVUS guidance using criteria such as stent CSA > distal 
reference lumen [41]. In contrast to the results mentioned 
above, the OPTICUS trial (optimization with IVUS to re-
duce stent restenosis) using the MUSIC criteria for IVUS 
guidance did not show a significant difference in 6- or 
12-month clinical outcomes [42]. However, in this study, 
only 56% of stents met all three MUSIC criteria. Many 
other trials in the BMS era used similar IVUS criteria, 
and two meta-analyses showed better outcomes of IVUS-
guided PCI than angiography-guided PCI, especially in 
terms of in-stent restenosis and target vessel revascular-
ization (TVR), but not in mortality or myocardial infarc-
tion [43,44].
In contrast to the BMS era, for IVUS-guided PCI with 
DES, few randomized studies showing clinical efficacy, 
preventing TVR or restenosis, or stent optimization under 
IVUS guidance have been carried out. In the HOME DES 
trial, optimal stent deployment was defined as complete 
apposition of the stent struts, no edge dissection, and ad-
equate stent expansion, defined as either MSA > 5.0 mm
2 
or > 90% of the distal reference lumen area [45]. In that 
study, no significant benefit in terms of TVR or clinical 
events was reported. A similar finding was also noted in 
the AVIO (angiography versus IVUS optimization) study 
in which optimal stent expansion was > 70% of the CSA of 
the chosen balloon [46]. However, attention should be paid 
to avoid stent underexpansion. Increasing evidence indi-
cates that IVUS-guided PCI may reduce the risk of stent 
thrombosis (ST) [47]. Stent underexpansion was demon-
strated to be one of the major causes of this disastrous 
complication, although the cause of ST is multifactorial 
[13,24,48,49]. In a substudy of the SIRIUS trial, adequate 
patency was defined as a follow-up IVUS MSA > 4.0 mm
2. 
When the adequate post-interventional MSA of SESs was 
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Figure 3. Sensitivity and specificity curves identified optimal cut-off values of final minimum stent cross-sectional area (CSA, A) and 
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defined as > 5.0 mm
2, the positive predictive value of pa-
tency was 90%, but the optimal cutoff value of BMS was 
defined as 6.5 mm [50]. Another study concerning SES 
failure also supported that MSA < 5.5 mm
2 and < 5.0 mm
2 
were the most important predictors of SES failure (Fig. 
3) [22,51]. Even if SES had a considerably lower optimal 
MSA threshold than BMS, these studies showed that un-
derexpansion remained the main cause of stent failure in 
DESs; at least a MSA < 5.0 mm should be avoided in non-
-left main (LM) lesions. In LM lesions, optimal MSA was 
reported in the MAIN-COMPARE (revascularization for 
unprotected left main coronary artery stenosis: compari-
son of percutaneous coronary angioplasty versus surgical 
revascularization) study to be > 8.7 mm
2 to prevent TLR 
[34].
Edge dissection, which is complicated by lumen nar-
rowing < 4 mm
2 or dissection angle ≥ 60°, has been as-
sociated with an increased incidence of early ST [49]; thus, 
additional stents may be needed to prevent ST. However, a 
minor dissection, detected by IVUS, may not be associated 
with an increased incidence of ST [52,53]. Although no 
consensus exists on an optimal strategy, in minor dissec-
tion, careful observation without stenting can be helpful.
Overall, the results discussed above encourage ensuring 
good apposition of stent struts to the vessel wall, such that 
the stent struts are not surrounded by lumen, adequate 
stent expansion to obtain MSA at least > 6.5 mm
2 for 
BMSs and > 5.0 mm
2 for DESs or MSA > 90% of the distal 
reference lumen CSA, and lack of major dissections, intra-
mural hematomas, and geographic misses.
outCoMeS of IVuS-guIDeD VeRSuS 
AngIogRApHy-guIDeD pCI
Numerous studies have evaluated the clinical benefits of 
IVUS-guided PCI compared with angiography-guided PCI 
in the BMS era [41-44]. The OPTICUS trial showed no sig-
nificant difference between IVUS- and angiography-guid-
ed PCI groups in terms of 6- and 12-month rates of death, 
myocardial infarction (MI), and TLR in 550 patients 
meeting the MUSIC criteria [42]. In contrast, the TULIP 
study demonstrated favorable angiographic and clinical 
outcomes in patients with long coronary lesions (> 20 mm) 
treated with a BMS (> 3 mm) under IVUS guidance [41]. In 
a meta-analysis of 2,193 patients from seven randomized 
trials, the rates of 6-month angiographic restenosis and 
target vessel revascularization were significantly lower in 
the IVUS-guided PCI group than the angiography-guided 
group (22% vs. 29%, p = 0.02 and 13% vs. 18%, p < 0.001, 
respectively), with no difference in the rates of death (2.4% 
vs. 1.6%, p = 0.18) or MI (3.6% vs. 4.4%, p = 0.51) [44], 
consistent with a previous meta-analysis [43].
To date, few studies have investigated the clinical ben-
efits of DES optimization under IVUS guidance compared 
with that of BMSs. The HOME DES IVUS (long-term 
health outcome and mortality evaluation after invasive 
coronary treatment using drug-eluting stents with or 
without IVUS guidance) study was a randomized trial to 
investigate clinical outcomes of IVUS-guided PCI with 
DESs. Although the IVUS-guided strategy resulted in the 
frequent use of adjunctive balloons and a larger size bal-
loon with higher pressure, no significant difference was 
observed in major adverse cardiac events or stent throm-
bosis in the study [45]. A similar retrospective study of 
IVUS-guided stent optimization also showed no signifi-
cant difference in the incidence of in-stent restenosis or 
neointimal volume between IVUS- versus angiography-
guided PCI [54]. Conversely, a study with a propensity-
matched analysis in 884 patients treated with DESs 
showed a significant reduction in the stent thrombosis rate 
at both 30 days (0.5% vs. 1.4%, p = 0.046) and 12 months 
(0.7% vs. 2.0%, p = 0.014) in the IVUS-guided PCI group 
[47].
Recently, a large “real world” registry from two Korean 
centers reported long-term outcomes of both IVUS- and 
angiography-guided PCI using BMS or DES implantation 
[55]. In total, 8,371 patients who underwent coronary 
stenting under IVUS guidance (4,627 patients) or angi-
ography guidance (3,744 patients) were consecutively 
enrolled, and 3-year adverse clinical outcomes were com-
pared between the groups using a Cox regression model 
and propensity score matching. In the overall population, 
the 3-year adjusted incidence of mortality was signifi-
cantly lower in the IVUS-guided PCI group compared 
with the angiography-guided PCI group (hazard ratio 
[HR], 0.70; 95% confidence interval [CI], 0.56 to 0.87; 
p = 0.001) (Fig. 4). In 2,715 matched pairs of the overall 
population, the IVUS-guided PCI group also had a lower 
mortality risk (HR, 0.71; 95% CI, 0.56 to 0.90; p = 0.005). 
However, IVUS-guided PCI did not influence the rates of 
myocardial infarction, target-vessel revascularization, or Yoon HJ and Hur SH. IVUS-guided stent optimization    35
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stent thrombosis in the overall or in the 2,715 matched-
pair populations. In the DES subpopulation, IVUS guid-
ance significantly reduced the 3-year adjusted mortality 
rate (HR, 0.55; 95% CI, 0.36 to 0.78; p = 0.001), which was 
not the case in the BMS subpopulation (HR, 0.79; 95% CI, 
0.59 to 1.05; p = 0.10). A propensity score matching analy-
sis of 201 matched patients from the MAIN-COMPARE 
study also demonstrated the importance of IVUS-guided 
PCI in unprotected left main disease [34]. In this analy-
sis, significantly lower incidence of 3-year mortality was 
noted in the IVUS-guided PCI group compared with the 
angiography-guided PCI group (4.7% vs. 13.6%, p = 0.048), 
but no significant difference was detected in the rates of 
TVR or MI. Notably, this benefit was found only for DES, 
and the benefit in mortality appeared to be primarily as-
sociated with reduced sudden cardiac death related to 
late stent thrombosis. Similar findings were also observed 
in patients undergoing PCI of non-left main bifurcations 
with DESs [35]. Taken together, the benefit of IVUS guid-
ance contributed primarily to decreased rates of stent 
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restenosis and repeated revascularization in the BMS era, 
whereas reduction of the stent thrombosis rate with pos-
sible improvement in mortality have predominated in the 
DES era.
ConCluSIonS
IVUS can provide direct cross-sectional images as well 
as longitudinal images of the coronary vessel wall. It has 
also contributed to our understanding of mechanisms 
in coronary atherosclerotic plaques and provided real-
time information at stented segments after coronary 
interventions. Possible criteria for optimal stent deploy-
ment by IVUS are complete stent apposition to the vessel 
wall, adequate stent expansion, and full lesion coverage 
without edge dissection (Fig. 5). Recent data suggest that 
IVUS-guided PCI may reduce long-term mortality when 
compared with angiography-guided PCI, particularly after 
DES implantation; thus, the clinical importance of IVUS-
guided PCI raised in the BMS era persists in the DES era. 
Optimization of stent deployment by IVUS during PCI 
may be considered as a routine practice in daily PCI, espe-
cially for complex lesion intervention.
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